Nat Turner, co-founder and CEO of Flatiron Health, explains how data can be used for finding potential patients to be included in clinical trials.
Nat Turner, co-founder and CEO of Flatiron Health, explains how data can be used for finding potential patients to be included in clinical trials.
Transcript (slightly modified)
How is data being used in clinical research to improve patient care?
A bunch of ways. The easiest to understand, or the simplest, is finding patients. So, you might have 800 patients coming in across your clinical in a day, you need to figure out which of those—most won’t be eligible—are potentially eligible for a clinical trial. Data is really the best way to do that since you can do it even before the patient walks in the door. That’s what we call patient finding.
The next is feasibility. So, if you’re a site and maybe you attract a certain type of patient population, maybe a doctor of yours specializes—whatever it might be—showing off your patient population to sponsors that are running trials is a very data-driven opportunity that could help you attract better studies. Also, once the study is live there’s a lot of data that could be used. Today, for example, you’re trying to compare a treatment to the real world, the standard of care, perhaps you could use the electronic health record data to model that standard of care, so you don’t have patients that could go on placebo, you could just model the standard of care. That’s a really exciting way data could disrupt clinical research.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More